| |
|
Drug Manufacturers - Other News
|
Sepracor slides on trial failure and Lunesta halt
Thu Jul 2 (AP)
Sepracor Inc. reported a pair of research setbacks, as it said a depression drug candidate failed in a clinical trial, and two studies of its insomnia drug Lunesta were stopped by the Food and Drug Administration.
|
|
Top-Ranked Analysts
|
Provided by StarMine
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 138B | | Price
/ Earnings: | 120.4 | | Price
/ Book: | 9.8 | | Net
Profit Margin (mrq): | 3.8% | | Price
To Free Cash Flow (mrq): | -170.6 | | Return
on Equity: | 3.7% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 1.0% |
|